PyMOL

Time Tracker

HipWall

Timer

Domain Not Resolving

DNSSEC

Font Awesome

reCAPTCHA

Cloudflare CDN

Cloudflare Hosting

Person Schema

Google

Google Cloud

Gravatar Profiles

Retired CHRO

Jennifer Daniel

SVP of Finance, Corporate Controller and Principal Accounting Officer

Jenny Herman

EVP & CFO

Joel Lebowitz

President, R&D - Therapeutics

Karen Akinsanya

President and CEO

Ramy Farid

VP & Head of Early Clinical Development

Daniel Weiss

Senior Vice President, Life Sciences Products

Matt Repasky

Business Management

Raghu Rangaswamy

Principal Associate

Aaron Seeburger

Director, Medicinal Chemistry

Adam Levinson

Vijay Pande

Timothy Wright

John Chodera

Wayne Guida

Matthew Jacobson

Ronald Levy

Barry Honig

President & CEO

Richard Friesner

Co-Founder

Pat Lorton

Yvonne Tran

Executive VP, Chief Legal Officer and Corporate Secretary

Chief Biomedical Scientist

Christopher Brown

Executive Director of Materials Discovery

Shane Brauner

SVP, Chief Information Officer

Mathew D. Halls

Senior Vice President, Materials Science

Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.

Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.

Software Companies that Exited (Top 10K)

United States Companies With Less Than $1B in Revenue (Top 10K)

Companies With Less Than $500M in Revenue (Top 10K)

Pharmaceutical Public Companies With Fewer Than 1000 Employees

Schrödinger develops a computational platform that facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas.

Schrödinger is deeply committed to investing in the science and talent that drive its computational platform.

Bill & Melinda Gates Foundation

Grant - Schrödinger

Post-IPO Equity - Schrödinger

Series E - Schrödinger

Venture Round - Schrödinger

WuXi AppTec

Series D - Schrödinger

Bill Gates

Series C - Schrödinger

Cascade Investment

Series B - Schrödinger

David E. Shaw

Series A - Schrödinger

New York

United States

North America

Schrödinger

Copernic Catalysts: Chemicals And E-Fuels Developer Raises $8 Million (Seed)

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger Broadens and Accelerates Predictive Toxicology Initiative

Schrodinger price target raised by $1 at Goldman Sachs, here's why

Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details

Schrödinger Reports Third Quarter 2024 Financial Results

Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis

Schrödinger to Present at Jefferies London Healthcare Conference

Schrödinger to Announce Third Quarter 2024 Financial Results on November 12

Biosimulation Market to Hit USD 9.18 Billion by 2029 with 16.7% CAGR | MarketsandMarkets™

A computational platform that uses physics-based modeling to discover and design molecules for therapeutics and materials research.

A platform for discovering and optimizing molecules to develop better therapeutics.

A platform for discovering, optimizing, and formulating advanced materials at the molecular level.

A drug discovery pipeline that uses Schrödinger's platform to develop therapeutics with high-value targets.

Educational resources and courses for learning and applying Schrödinger's technology in digital chemistry.

Tools for discovering and optimizing inorganic materials using computational workflows and machine learning.

Canada

India

Asia

South Korea

Italy

Europe

HTML5

Disqus

jQuery

Comodo PositiveSSL Certificates

Apache Server

Modernizr

Google Tag Manager

F5 NGINX

Office 365

Fonts.com

Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Schrödinger, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 6, 2024 7:27 PM	9efd9b71
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 6, 2024 7:27 PM	87f7e784
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	41fedd3a
crunchbase profile	general	Nov 22, 2024 9:33 AM	180e29d3
li profile	general
translate crunchbase fundingrounds	general	Nov 22, 2024 2:07 PM	76698131
peers	general
news basic	general	Mar 6, 2024 7:27 PM	37a7af94
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:SCHRODINGER

Schrödinger, Inc.

Last Close

20.37

22/11 21:00

Market Cap

1.50B

Beta: -

Volume Today

623.33K

Avg: -